Shawn Wettig

Dr. Shawn Wettig

School of Pharmacy, University of Waterloo, 200 University Ave. W., Waterloo, ON, N2L 3G1, Canada
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
SCShannon P. Callender
Shannon P. Callender
JMJessica A. Mathews
Jessica A. Mathews
KKKatherine Kobernyk
Katherine Kobernyk
SWShawn Wettig
Shawn Wettig

1 March 2001 in Journal of Colloid and Interface Science
Verified
Journal Article
Closed access
SWShawn Wettig
Shawn Wettig
RVR.E. Verrall
R.E. Verrall

2 May 2013 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
SMShadi H. Moghadam
Shadi H. Moghadam
ESEvi Saliaj
Evi Saliaj
SWShawn Wettig
Shawn Wettig
CDChilbert Dong
Chilbert Dong
MIMarina V. Ivanova
Marina V. Ivanova
MFMarianna Foldvari
Marianna Foldvari

5 June 2002 in Langmuir
Verified
Journal Article
Closed access
SWShawn Wettig
Shawn Wettig
PNPawel Nowak
Pawel Nowak
RVR. E. Verrall
R. E. Verrall

19 January 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
AAAhsan Aamir Ayub
Ahsan Aamir Ayub
SWShawn Wettig
Shawn Wettig
Drug delivery to the brain has been one of the toughest challenges researchers have faced to develop effective treatments for brain diseases. Owing to the blood–brain barrier (BBB), only a small portion of administered drug can reach the brain. A consequence of that is the need to administer a higher dose of the drug, which, expectedly, leads to a variety of unwanted side effects. Research in a variety of different fields has been underway for the past couple of decades to address this very serious and frequently lethal problem. One area of research that has produced optimistic results in recent years is nanomedicine. Nanomedicine is the science birthed by fusing the fields of nanotechnology, chemistry and medicine into one. Many different types of nanomedicine-based drug-delivery systems are currently being studied for the sole purpose of improved drug delivery to the brain. This review puts together and briefly summarizes some of the major breakthroughs in this crusade. Inorganic nanoparticle-based drug-delivery systems, such as gold nanoparticles and magnetic nanoparticles, are discussed, as well as some organic nanoparticulate systems. Amongst the organic drug-delivery nanosystems, polymeric micelles and dendrimers are discussed briefly and solid polymeric nanoparticles are explored in detail.

1 January 2019 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
OMOsama A. Madkhali
Osama A. Madkhali
GMGeorge Mekhail
George Mekhail
SWShawn Wettig
Shawn Wettig